FindTrial
Sign In

MEDI4736 (Durvalumab)

BIOLOGICAL6 trials

Sponsors

Kyowa Kirin, Inc., AstraZeneca, Royal Marsden NHS Foundation Trust

Conditions

Adenocarcinoma of the Gastro-oesophageal JunctionAdenocarcinoma of the OesophagusAdenocarcinoma of the StomachAdvanced Solid MalignanciesAdvanced Solid TumorsNon - Small Cell Lung Cancer NSCLCNon-Small-Cell Lung Carcinoma NSCLCUrothelial Cancer

Phase 1

Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors
CompletedNCT02301130
Kyowa Kirin, Inc.Advanced Solid Tumors
Start: 2014-11-26End: 2018-03-05Updated: 2024-04-25

Phase 2

Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial
Active, not recruitingNCT02678182
Royal Marsden NHS Foundation TrustAdenocarcinoma of the Gastro-oesophageal Junction, Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Stomach
Start: 2015-02-28End: 2027-06-30Updated: 2025-06-10

Phase 3

A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
CompletedNCT02352948
AstraZenecaNon - Small Cell Lung Cancer NSCLC
Start: 2015-01-13End: 2023-08-30Updated: 2024-07-26
Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
Active, not recruitingNCT02453282
AstraZenecaNon-Small-Cell Lung Carcinoma NSCLC
Start: 2015-07-21End: 2026-12-31Updated: 2026-03-02
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
Active, not recruitingNCT02516241
AstraZenecaUrothelial Cancer
Start: 2015-11-02End: 2026-12-31Updated: 2026-01-28
An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.
CompletedNCT03084471
AstraZenecaAdvanced Solid Malignancies
Start: 2017-06-05End: 2022-12-16Updated: 2022-12-22

Related Papers

Abstract 4123: Dissecting the baseline tumor microenvironment in mNSCLC by transcriptional profiling identifies tumor microenvironmental conditions predictive for immunotherapy response
Cancer Research2026-04-03
Enhanced patient selection with quantitative continuous scoring of PD-L1 expression for IO treatment in metastatic NSCLC
npj Precision Oncology2025-09-18
Evaluation of the Effectiveness and Safety Profile of First-Line Immune Checkpoint Inhibitors Combined with Chemotherapy in Pulmonary Sarcomatoid Carcinoma.
2025-06-09
Abstract 5781: Comparing prognostic association of manual vs. artificial intelligence derived quantifications from baseline computed tomography scans in MYSTIC, a global phase 3 trial for treatment of metastatic non-small cell lung cancer
Cancer Research2025-04-21
Abstract 7611: Circulating blood RNAseq detects activation of immune system and predicts response to immunotherapy in bladder cancer
Cancer Research2024-03-221 citations
Abstract 2492: Enhanced patient selection for anti-PD-L1 treatment in metastatic NSCLC with quantitative continuous scoring of PD-L1
Cancer Research2024-03-221 citations
INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors.
2024-02-1310 citations
Exploratory analysis of biomarkers of response to durvalumab in advanced HER2-negative oesophago-gastric adenocarcinoma within a phase 2 clinical trial.
Journal of Clinical Oncology2024-01-20
MicroRNAs as biomarkers for trastuzumab-based therapy in HER2-positive advanced oesophago-gastric cancer patients
Frontiers in Oncology2023-11-293 citations
605 Computational pathology-based digital twins enable the discovery of predictive biomarkers for precision immuno-oncology
Regular and Young Investigator Award Abstracts2023-10-31
Real-world response rates and clinical outcomes of patients treated with first-line (1L) platinum-based chemotherapy (PBC) in advanced urothelial cancer (aUC).
Journal of Clinical Oncology2023-06-016 citations
MicroRNAs (miRs) as biomarkers of resistance to trastuzumab in HER2-positive oesophago-gastric cancer: Sub-study within the Planning Treatment for Oesophago-Gastric Cancer—A Randomised Maintenance Therapy Trial (PLATFORM).
Journal of Clinical Oncology2023-01-241 citations
583 Quantitative computational assessment of PD-L1 enables robust patient selection for biomarker-informed anti-PD-L1 treatment of NSCLC patients
Regular and Young Investigator Award Abstracts2022-11-012 citations
591 Immunogenicity of durvalumab: analysis of pooled pan-tumor data
Regular and Young Investigator Award Abstracts2022-11-01
Prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma (mUC) treated with durvalumab (D) with or without tremelimumab (T) in the DANUBE study.
Journal of Clinical Oncology2022-06-011 citations
Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma.
2022-01-1510 citations
RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse.
2021-09-1639 citations
Abstract 489: Association between immune-mediated adverse events and survival in patients with metastatic non-small cell lung cancer treated with durvalumab and tremelimumab
Cancer Research2021-07-01
How patients being treated for non-small cell lung cancer value treatment benefit despite side effects.
2021-05-314 citations
Maintenance durvalumab after first-line platinum-based chemotherapy in advanced oesophago-gastric (OG) adenocarcinoma: Results from the PLATFORM trial.
Journal of Clinical Oncology2021-05-209 citations

25 more papers not shown